ReachRxResearch
Home
Research
Sign Up
Azacitidine maintenance after allogeneic hematopoietic stem cell transplantation in high-risk AML: a single-center retrospective study
Back to Research Hub
  1. Home
  2. Research Hub
  3. Azacitidine maintenance after allogeneic…

Azacitidine maintenance after allogeneic hematopoietic stem cell transplantation in high-risk AML: a single-center retrospective study

Bone Marrow Transplantation·September 14Open Access
HematologyLimited evidenceAcute Myeloid LeukemiaRetrospective Cohort StudyHypomethylating AgentAdultAzacitidine

Summary

View source

What was studied

This single-center retrospective study evaluated azacitidine as maintenance therapy after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with high-risk acute myeloid leukemia (AML).

Study limitations

Single-center retrospective design limits generalizability and introduces selection bias; no randomized comparator arm; sample size and follow-up duration are not reported in the available metadata.

Clinical implications

Azacitidine maintenance post-allo-HSCT may be considered in high-risk AML, but clinicians should interpret findings cautiously given the retrospective, single-center nature of this study and await prospective data.

Caveats

  • The full text of this paper was not available — only metadata (title, journal, DOI, publication date) was provided. All structured outputs are inferred from the title and standard knowledge of the study type; specific results, sample sizes, and outcomes could not be extracted. Clinicians should consult the full publication for definitive data.

Related Questions

Explore related topics

What is the evidence for azacitidine maintenance after allogeneic stem cell transplant in AML?How does post-transplant maintenance therapy affect relapse rates in high-risk AML?Are there randomized trials comparing hypomethylating agents as maintenance after allo-HSCT in AML?

Publication Details

Year
2026
Journal
Bone Marrow Transplantation
Source
View article
Keep scrolling
More content below.
Up Next